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Objectives The goal of this study was to evaluate the relationship between the presence of sinus rhythm and outcomes in
patients with a history of congestive heart failure (CHF) and atrial fibrillation (AF).
Background The value of sinus rhythm maintenance in patients with AF and heart failure (HF) is uncertain.
Methods A total of 1,376 patients with AF, ejection fraction 35%, and heart failure symptoms were randomized to a
rhythm- or rate-control strategy. Detailed efficacy analyses were used to evaluate the independent effects of
treatment strategy and the presence of sinus rhythm on cardiovascular outcomes.
Results Overall, 445 (32%) patients died and 402 (29%) experienced worsening HF. The rhythm-control strategy was not
predictive of cardiovascular mortality (hazard ratio [HR]: 0.90, 95% confidence interval [CI]: 0.70 to 1.16; p 
0.41), all-cause death (HR: 0.86, 95% CI: 0.69 to 1.08; p  0.19), or worsening HF (HR: 0.86, 95% CI: 0.68 to
1.10; p  0.23). In analyses devised to isolate the effect of underlying rhythm, sinus rhythm was not associated
with cardiovascular mortality [HR: 1.22, 95% CI: 0.80 to 1.87; p  0.35), total mortality [HR: 1.11, 95% CI: 0.78
to 1.58; p  0.57), or worsening HF [HR: 0.62, 95% CI: 0.37 to 1.02; p  0.059).
Conclusions A rhythm-control strategy or the presence of sinus rhythm are not associated with better outcomes in patients
with AF and CHF. (J Am Coll Cardiol 2010;55:1796–802) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.023H
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Come epidemiologic studies suggest that atrial fibrillation
AF) is an independent predictor of mortality in patients
ith congestive heart failure (CHF) (1). Restoration and
aintenance of sinus rhythm (rhythm-control) are often
ttempted in the hope of reducing mortality and prevent-
ng (HF) recurrences. This strategy was recently com-
ared with a simpler “rate-control” strategy in the ran-
omized AF-CHF (Atrial Fibrillation and Congestive
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imilar in the 2 treatment arms, whereas the rate-control
trategy was associated with fewer hospitalizations and
ardiac procedures.
In the AF-CHF trial, 15% of patients crossed over
rom one strategy to the other. Moreover, at any given
ime, normal sinus rhythm was present in 30% to 40% of
atients assigned to the rate-control strategy, whereas AF
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April 27, 2010:1796–802 Sinus Rhythm and Survival in AF and CHFt least once in 58% of patients randomized to rhythm-
ontrol strategy. It remains to be determined whether
aintenance of sinus rhythm in patients with HF and a
istory of AF portends a survival advantage (as contrasted
ith assignment to a rhythm-control strategy). We per-
ormed a detailed efficacy analysis of the AF-CHF trial to
valuate the relationship between survival, actual treat-
ent strategy, and prevalent cardiac rhythm in patients
ith AF and CHF.
ethods
n the AF-CHF trial, 1,376 patients with symptomatic HF,
eft ventricular ejection fraction 35%, and recent AF were
andomized from 123 centers to either the rhythm- or
ate-control strategy (2). Patients were followed at 3 weeks,
months, every 4 months for 48 months, and every 6
onths thereafter. At each visit, a medical history and
lectrocardiogram were obtained, and the investigator noted
hether the assigned treatment strategy had been changed.
f ECG-documented AF occurred between visits, investi-
ators noted whether it was intermittent or continuous.
Objectives of the current study were 2-fold: 1) to conduct
n on-treatment efficacy analysis; and 2) to isolate the effect
f underlying rhythm on clinical outcomes. Similar to the
riginal intention-to-treat analysis (2), cardiovascular mor-
ality was considered the primary outcome. Secondary
utcomes consisted of all-cause mortality and worsening
F. The latter was defined as the occurrence of HF
equiring an overnight hospital or emergency department
tay or leading to a change in treatment strategy. All
utcomes were adjudicated by an events committee blinded
o the treatment assignment.
tatistical analyses. Continuous variables are summarized
y mean  SD. Categorical variables are represented by
requencies and percentages. Two-group baseline comparisons
ere performed by using the Student t or chi-square test where
ppropriate. Event-free survival was plotted using the Kaplan-
eier method and compared by log-rank statistics. Univariate
nd multivariate Cox regression models (described in later text)
onsidered 22 static baseline and 4 time-dependent covariates,
isted in Table 1. For time-dependent medical therapy covari-
tes, a patient was considered to have used a drug if it was
ecorded during the evaluation preceding the interval of inter-
st. Variables that were significant at the 0.2 level in univariate
nalyses were included in backward-selection multivariate Cox
odels and retained if associated with p values 0.01. Analyses
ere performed with SAS software version 9.1 (SAS Institute,
ary, North Carolina).
n-treatment analyses. For on-treatment analyses, patient
ime was ascribed to the treatment category actually received as
pposed to one that is randomly assigned (as in an intention-to-
reat approach). The following 2 analyses were performed.
FFICACY ANALYSIS BY INITIALLY ASSIGNED TREATMENT.
atients were censored at the time of crossover from the
andomly allocated treatment strategy. Because systematic
A
3ifferences may exist between pa-
ients who crossover from one di-
ection to the other, disparities in
aseline characteristics were ad-
usted for in multivariate Cox re-
ression analyses. To address bi-
ses introduced by right-censoring
atients who crossed over, a sepa-
ate analysis restricted the study
opulation to the 85% of pa-
ients who remained on their ini-
ially assigned treatment strategy
hroughout the study.
IME-DEPENDENT ON-TREATMENT EFFICACY ANALYSIS.
reatment strategy was modeled as a time-dependent co-
ariate in an analysis that included all patients, without
ensoring at the time of crossover. With this approach,
atient time was attributed to the treatment strategy in the
ime period under observation. Multivariate Cox regression
odels that included treatment strategy as a time-
ependent exposure variable were adjusted for the covariates
isted in Table 1 (excluding the covariate AF vs. sinus rhythm).
ardiac rhythm analysis. To isolate the effect of underly-
ng rhythm irrespective of treatment strategy, the primary
aseline and Time-Dependent Covariatessed Cox Proportional Hazards Mod lsTable 1 Baseline and Time-Depen nt CovariatesUsed in Cox Proportional Hazards Models
Baseline covariates
Age at randomization
Sex
Body mass index
History of coronary artery disease
History of hypertension
History of diabetes
History of stroke or transient ischemic attacks
Left ventricular ejection fraction
NYHA functional class (I to II vs. III to IV)
Type of atrial fibrillation (paroxysmal vs. persistent)
Duration of atrial fibrillation history
QRS duration
ACE inhibitors or ARB
HMG-CoA reductase inhibitors
Aldosterone antagonists
Oral anticoagulants
Antiplatelet agents
Echocardiographic left atrial size
Echocardiographic mitral regurgitation (none or mild vs. moderate or severe)
Serum sodium
Serum creatinine
Implantable cardioverter-defibrillator
Time-dependent covariates
Atrial fibrillation versus sinus rhythm
Digoxin
Beta-blocker
Antiarrhythmic drug therapy
Abbreviations
and Acronyms
AF  atrial fibrillation
CHF  congestive heart
failure
CI  confidence interval
ECG  electrocardiogram
HF  heart failure
HR  hazard ratioCE  angiotensin-converting enzyme; ARB  angio
-hydroxy-3-methylglutaryl coenzyme A; NYHA  New Yortensin-receptor blocker; HMG-CoA 
k Heart Association.
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Sinus Rhythm and Survival in AF and CHF April 27, 2010:1796–802nalysis consisted of modeling presence of AF versus sinus
hythm as a time-dependent covariate. Time intervals be-
ween visits were divided into quartiles. Sinus rhythm or AF
as assigned to each of 4 equal time segments for every patient
n the basis of ECG documentation and the investigators’
etermination of AF occurrence between visits, as portrayed in
igure 1A. Cox proportional hazards models, with underlying
hythm represented as a time-dependent covariate, considered
he variables listed in Table 1. In addition, for each patient, the
stimated proportion of time spent in sinus rhythm was
alculated by dividing the total time in sinus rhythm by the
ollow-up duration. Patients were divided into 2 groups based
n whether their proportion of time spent in sinus rhythm was
qual or superior (high prevalence) or inferior (low prevalence)
Figure 1 Classification and Distribution of Patient Time in Sinu
(A) Illustration of how patient time in sinus rhythm was calculated. For each patie
nated sinus rhythm or atrial fibrillation on the basis of the electrocardiogram (ECG
tion, investigators recorded whether ECG-documented atrial fibrillation occurred be
(possible responses indicated with X). All possible combinations of data from thes
of time in sinus rhythm for the 1,316 patients undergoing rhythm analysis. The nuo the median value. Kaplan-Meier product limit curves were
lotted for illustrative purposes.
esults
ll 1,376 patients (82% male, mean age 67  11 years)
ere included in this analysis and followed for an average
f 37  19 months. Overall, 445 (32%) patients died,
ith 80% of deaths classified as cardiovascular. At least 1
pisode of worsening heart failure occurred in 402 (29%)
atients.
n-treatment analysis. EFFICACY ANALYSIS BY INITIALLY
SSIGNED TREATMENT. Over the course of the study, 208
15%) patients crossed over at least once from their assigned
thm
time interval between visits was divided in quartiles, with each quartile desig-
linical visit information. All patients had an ECG at each scheduled visit. In addi-
scheduled visits and whether recurrences were continuous or intermittent
urces of information are displayed in table format. (B) The resulting distribution
of patients is plotted versus the percentage of time in sinus rhythm.s Rhy
nt, the
) and c
tween
e 2 so
mber
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April 27, 2010:1796–802 Sinus Rhythm and Survival in AF and CHFtrategy. Overall, 144 (21%) of 682 patients randomized to
he rhythm-control strategy and 64 (9%) of 694 randomized
o the rate-control strategy crossed over to the alternate
reatment strategy. A single crossover occurred in 190
atients, whereas 18 patients crossed over more than once (2
o 5 times). An on-treatment analysis of cardiovascular
ortality is depicted in Figure 2. In Figure 2A, the analysis
s restricted to the 1,168 patients who never crossed over,
hereas all 1,376 patients were included in Figure 2B, with
ensoring at the time of first crossover. In each case, there
as no significant difference in cardiovascular mortality
etween groups.
IME-DEPENDENT ON-TREATMENT EFFICACY ANALYSIS.
he results of multivariate regression analysis incorporating
reatment strategy are shown in Table 2. As a time-
Figure 2 On-Treatment Efficacy Analysis
(A) Freedom from cardiovascular mortality according to the assigned treatment
strategy in the 1,168 patients who never crossed over during the course of the
study. (B) Freedom from cardiovascular mortality according to the randomized
treatment strategy is shown for all 1,376 patients, with censoring at the time
of crossover. In each case, no significant difference in cardiovascular mortality
was observed.Tependent variable, the current rhythm versus rate control
reatment strategy was not predictive of cardiovascular
ortality, total mortality, or worsening HF.
esults of Multivariate Regression Modelncorporating Rhythm-Control StrategyTable 2 Results of Multivariate Regression ModelIncorporating Rhythm-Control Strategy
Clinical Parameter HR (95% CI) p Value
Cardiovascular mortality
QRS duration, ms 1.01 (1.00–1.01) 0.002
Spironolactone use 1.68 (1.30–2.17) 0.0001
Coronary artery disease 2.05 (1.59–2.66) 0.0001
Oral anticoagulants 0.55 (0.40–0.77) 0.0005
Beta-blockers 0.66 (0.49–0.87) 0.0034
Rhythm-control strategy 0.90 (0.70–1.16) 0.41
Total mortality
Age, yrs 1.02 (1.00–1.03) 0.0086
NYHA functional classes III to IV 1.47 (1.17–1.85) 0.0009
Spironolactone 1.51 (1.21–1.89) 0.0003
Coronary artery disease 1.97 (1.56–2.50) 0.0001
Oral anticoagulants 0.55 (0.41–0.73) 0.0001
Beta-blockers 0.70 (0.55–0.90) 0.0059
Rhythm-control strategy 0.86 (0.69–1.08) 0.19
Worsening heart failure
Body mass index 0.97 (0.94–0.99) 0.0090
NYHA functional classes III to IV 1.56 (1.21–2.01) 0.0004
QRS duration, ms 1.01 (1.00–1.01) 0.0002
Coronary artery disease 1.81 (1.38–2.36) 0.0001
Diabetes 1.58 (1.19–2.08) 0.0013
Moderate-severe mitral regurgitation 1.46 (1.14–1.86) 0.0027
Serum creatinine, mmol/l 1.003 (1.00–1.01) 0.0007
Antiplatelet therapy 1.43 (1.11–1.84) 0.0064
Rhythm-control strategy 0.86 (0.68–1.10) 0.23
I  confidence interval; HR  hazard ratio; NYHA  New York Heart Association.
esults of Multivariate Regression Analysisncorporating Cardiac Rhythm StatusTable 3 Results of Multivariate Regression AnalysisIncorporating Cardiac Rhythm Status
Clinical Parameter HR (95% CI) p Value
Cardiovascular mortality
NYHA functional classes III to IV 1.78 (1.16–2.73) 0.008
Coronary artery disease 2.0 (1.29–3.08) 0.0018
Previous stroke/TIA 2.47 (1.41–4.34) 0.0017
Moderate-severe mitral regurgitation 2.02 (1.33–3.08) 0.001
Oral anticoagulants 0.38 (0.23–0.65) 0.0003
Atrial fibrillation 1.22 (0.80–1.87) 0.35
Total mortality
NYHA functional classes III to IV 1.88 (1.31–2.69) 0.0006
Coronary artery disease 2.23 (1.54–3.23) 0.0001
Previous stroke/TIA 2.23 (1.38–3.62) 0.0012
Moderate-severe mitral regurgitation 1.65 (1.15–2.35) 0.0061
Oral anticoagulants 0.48 (0.30–0.77) 0.0025
Atrial fibrillation 1.11 (0.78–1.58) 0.57
Worsening heart failure
Coronary artery disease 2.79 (1.66–4.69) 0.0001
Moderate-severe mitral regurgitation 2.29 (1.39–3.78) 0.0012
ACE inhibitors or ARB 0.27 (0.11–0.65) 0.0034
Atrial fibrillation 0.62 (0.37–1.02) 0.06IA  transient ischemic attack; other abbreviations as in Tables 1 and 2.
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Sinus Rhythm and Survival in AF and CHF April 27, 2010:1796–802ardiac rhythm analysis. Analyses of underlying cardiac
hythm were limited to the 1,316 (96%) patients for whom
CGs were available. This population was followed for 4,181
atient-years, with a median time between visits of 3.7 months.
n primary time-dependent efficacy analyses devised to isolate
he effect of underlying rhythm on outcomes, AF was not
redictive of cardiovascular mortality, total mortality, or wors-
ning HF. The results of these analyses are displayed in Table
. The proportion of time spent in sinus rhythm was asym-
etrical, with a median of 61%, and most patients clustered
ither below 20% or above 80% (Fig. 1B). The clinical
haracteristics of patients with a high (61%; median 92%)
ersus low (61%; median 12%) prevalence of sinus rhythm
re summarized in Table 4. Figure 3 depicts the absence of
ignificant differences in cardiovascular mortality, total mortal-
ty, and worsening HF in patients with a high versus low
Characteristics of Patients With High Versus LoTable 4 Characteristics of Patients With Hig
H
Proportion of time in sinus rhythm, %
Randomization to rhythm control
Age, yrs
Male sex
Nonwhite ethnicity*
Body mass index, kg/m2
Left ventricular ejection fraction, %
Coronary artery disease
Hypertension
Diabetes
Previous stroke or TIA
NYHA functional class III or IV
Paroxysmal atrial fibrillation
History of atrial fibrillation 6 months
Atrial fibrillation on baseline ECG
History of cardioversion
Left atrial dimension, mm
QRS width, ms
Previous hospitalization
For atrial fibrillation
For congestive heart failure
Medical therapy
ACE inhibitor
ARB
Aldosterone antagonist
Beta-blocker
Antiarrhythmic drug
Anticoagulant
Antiplatelet agent
Lipid-lowering agent
Digitalis
Moderate or severe mitral regurgitation
Serum sodium, mmol/l
Serum creatinine, mmol/l
Implantable cardioverter-defibrillator
Values are mean  SD or n (%). *Ethnicity was self-reported.
ECG  electrocardiogram; other abbreviations as in Tables 1 to 3.revalence of sinus rhythm. siscussion
he AF-CHF trial was powered and designed primarily for
n intention-to-treat effectiveness analysis. As with most
arge randomized trials, complementary analyses may shed
ight on issues of efficacy. For example, treatment crossovers
ay dilute the beneficial effects of a therapy and occurred at
east once in 15% of patients during the course of the
F-CHF trial (similar to previous rate- vs. rhythm-control
rials) (3). In addition, the limited efficacy of maintaining
inus rhythm and the potential harmful effects of current
herapy for AF may explain the lack of benefit of a
hythm-control strategy, even if sinus rhythm were associ-
ted with a better outcome. In the current analysis, we
ocused on 2 important components of efficacy: the com-
arative efficacy of defined rhythm- versus rate-control
valence of Sinus Rhythmrsus Low Prevalence of Sinus Rhythm
revalence
663)
Low Prevalence
(n  653) p Value
 11 12 18
1 (71) 182 (28) 0.0001
 11.3 67.3 10.6 0.053
0 (81) 536 (82) 0.766
2 (14) 95 (15) 0.110
 4.9 28.4 5.7 0.002
 6 27 6 0.783
4 (47) 312 (48) 0.791
6 (48) 309 (47) 0.901
0 (20) 140 (21) 0.411
9 (10) 52 (8) 0.125
8 (27) 229 (35) 0.001
7 (40) 135 (21) 0.0001
4 (34) 340 (52) 0.0001
0 (41) 491 (75) 0.0001
3 (35) 231 (35) 0.946
 7 50 7 0.0001
 28 114 32 0.832
5 (52) 350 (54) 0.590
3 (53) 363 (56) 0.393
1 (86) 565 (87) 0.833
7 (12) 64 (10) 0.288
0 (44) 298 (46) 0.489
9 (80) 512 (78) 0.534
2 (46) 272 (42) 0.154
1 (85) 603 (92) 0.0001
0 (42) 223 (34) 0.003
8 (42) 282 (43) 0.645
8 (63) 427 (65) 0.375
3 (32) 209 (34) 0.561
 4 140 3 0.001
 36 113 45 0.520
0 (8) 43 (7) 0.498w Preh Ve
igh P
(n 
92
47
66.1
54
9
27.5
27
31
31
13
6
17
26
22
27
23
48
114
34
35
57
7
29
52
30
56
28
27
41
20
139
111
5trategies and the impact of sinus rhythm on outcomes.
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April 27, 2010:1796–802 Sinus Rhythm and Survival in AF and CHFBecause benefits of randomization are not fully carried
ver to efficacy analyses, our statistical approach combined
arious complementary methodologies to address potential
election biases and confounders. Censoring patients at the
ime of crossover or entirely excluding patients who crossed
ver yielded similar outcomes in patients randomized to
ither strategy. Moreover, in an analysis that controlled for
otential confounders and made full use of the dataset (i.e.,
ithout left truncation or right-censoring), treatment strat-
gy modeled as a time-dependent variable was not associ-
ted with mortality or worsening HF.
Cardiac rhythm analyses also failed to demonstrate an
ndependent impact of underlying rhythm on outcomes.
hen the population was partitioned into 2 groups accord-
ng to the proportion of time spent in sinus rhythm (i.e.,
igh [median 92%] vs. low [median 12%]), no differences in
utcomes were found. In a multivariate analysis that con-
rolled for potential confounders and modeled underlying
hythm as a time-dependent variable, the presence of AF
as not predictive of cardiovascular mortality, total mortal-
ty, or worsening HF. Clinical factors previously associated
ith poor survival in patients with heart failure were
onfirmed by our study (4), including older age, coronary
rtery disease, advanced New York Heart Association func-
ional class, prolonged QRS duration, and previous cere-
rovascular events. In addition, we found that oral
nticoagulation therapy was associated with improved
urvival, consonant with proven protective effects in
atients with AF and risk factors for stroke (5).
Although our results seem to contrast with findings from
FFIRM (Atrial Fibrillation Follow-up Investigation of
hythm Management) (6), inconsistencies may reflect, in
art, the different study populations, treatment strategies,
nd means of ascertaining time-dependent exposures. In
FFIRM, sinus rhythm modeled as a time-dependent
ovariate was associated with a better prognosis and antiar-
hythmic drug use with a poorer outcome. Importantly, the
F-CHF trial was restricted to patients with severe systolic
ysfunction and symptomatic HF, whereas few patients in
FFIRM had left ventricular dysfunction. In addition,
lmost all patients in the rhythm-control arm of the
F-CHF trial received amiodarone, whereas other antiar-
hythmic drugs were used in AFFIRM, including sodium
hannel blockers, which have previously been associated
ith increased mortality (7). Finally, our study design
ermitted a more comprehensive classification scheme for
ime spent in AF, incorporating 2 sources of information. In
ontrast, AFFIRM relied exclusively on ECGs obtained at
ach visit. Previous studies of HF have provided inconsis-
ent results, some suggesting that AF is associated with a
oorer prognosis (1). These discrepancies may be due, in
art, to differences in study populations with variable
ncidences of AF and distributions of prognostically impor-
ant factors such as age, left ventricular ejection fraction, and
omorbidities that may confound the relationship betweenFigure 3 Efficacy Analysis by Underlying Rhythm
Freedom from cardiovascular mortality (A), total mortality (B), and worsening
heart failure (C) is shown for patients with a low versus high prevalence of
sinus rhythm. No significant differences were noted between groups.F and outcomes. The most plausible explanation for our
fi
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Sinus Rhythm and Survival in AF and CHF April 27, 2010:1796–802ndings is that AF is a marker of more advanced disease but
hat it is not etiologically linked to poorer outcome. Indeed,
atients with a higher AF burden had a longer history of
F, more persistent forms, larger left atrial dimensions, and
orse New York Heart Association functional class. This
uggests a greater degree of structural changes associated
ith heart disease, perhaps explaining why AF per se was
ot independently associated with outcome. These findings
re consistent with observations by Yamada et al. (8) who
emonstrated slower atrial conduction and elevated atrial
atriuretic factor in HF patients in whom AF subsequently
eveloped. Amiodarone was used to maintain sinus rhythm
n the vast majority of our patients, thus reflecting practice
n the many constituencies across 4 continents in which our
tudy was conducted. Recent reports of pulmonary vein
blation in selected patients with HF suggested important
mprovements in ventricular function (9,10). However,
hese series have been small and lacked hard clinical out-
omes. Larger randomized trials with appropriate end
oints are needed to fully assess the invasive strategy in
atients with HF.
tudy limitations. Efficacy analyses have inherent limita-
ions that arise from loss of the randomization effect. We
sed a multifaceted analysis with complementary ap-
roaches devised to minimize systematic bias. Importantly,
he consistency of our analyses suggests that our findings
ere robust to specific approaches. It is well-known that
pisodes of AF may be silent, leading to underestimation of
he true AF burden (11). However, this potential limitation
oes not apply to on-treatment analyses, underscoring the
mportance of the various approaches to assessing efficacy.
onclusions
rhythm-control strategy is not associated with better
utcomes in patients with AF and CHF, even when analysis
s performed to consider efficacy in sinus rhythm mainte-
ance. Clinical implications are substantial, consistent with
ll previous clinical trials comparing rate- versus rhythm-
ontrol strategies and support the notion that rate control is
K
yn acceptable primary treatment option in a sizable propor-
ion of the population with AF with symptomatic HF and
rreversible left ventricular systolic dysfunction.
eprint requests and correspondence: Dr. Mario Talajic, Re-
earch Center, Montreal Heart Institute, 5000 Bélanger Street,
ontreal, Quebec H1T 1C8, Canada. E-mail: mario.talajic@
cm-mhi.org.
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